Issue 1/2016
Content (25 Articles)
Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy
Paola Perego, Jacques Robert
The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
Antonio Ruggiero, Daniela Rizzo, Giovanna Trombatore, Palma Maurizi, Riccardo Riccardi
Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice
S. M. Attia, S. F. Ahmad, S. A. Bakheet
Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma
Hiroaki Yanagimoto, Sohei Satoi, Masayuki Sho, Takahiro Akahori, Tomohisa Yamamoto, Satoshi Hirooka, So Yamaki, Masaya Kotsuka, Hironori Ryota, Shoichi Kinoshita, Satoshi Nishiwada, Minako Nagai, Naoya Ikeda, Koji Tsuta, Yoshiyuki Nakajima, Masanori Kon
Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human
Nigel J. Waters, Sherri A. Smith, Edward J. Olhava, Kenneth W. Duncan, Richard D. Burton, James O’Neill, Marie-Eve Rodrigue, Roy M. Pollock, Mikel P. Moyer, Richard Chesworth
Malformin A1 promotes cell death through induction of apoptosis, necrosis and autophagy in prostate cancer cells
Yongqing Liu, Ming Wang, Dawei Wang, Xiaobin Li, Wei Wang, Hongxiang Lou, Huiqing Yuan
Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer
Angelica L. Quartino, Carina Hillenbach, Jing Li, Hanbin Li, Russell D. Wada, Jennifer Visich, Chunze Li, Dominik Heinzmann, Jin Y. Jin, Bert L. Lum
Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies
Feng Jin, Yuying Gao, Huafeng Zhou, Lorna Fang, Xiaoming Li, Srini Ramanathan
A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors
Patrick Schöffski, Philippe Aftimos, Herlinde Dumez, Amélie Deleporte, Katrien De Block, Jo Costermans, Maureen Billiet, Marie-Anne Meeus, Chooi Lee, David Schnell, Rainer-Georg Goeldner, Ahmad Awada
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
S. Cereda, M. Milella, S. Cordio, F. Leone, G. Aprile, A. Galiano, S. Mosconi, E. Vasile, D. Santini, C. Belli, A. Auriemma, A. Novarino, V. Vaccaro, C. Martines, D. Marino, S. E. Lutrino, V. Palazzo, B. Reinach, L. Aldrighetti, M. Reni
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Elena Mazza, Alba Brandes, Silvia Zanon, Marika Eoli, Giuseppe Lombardi, Marina Faedi, Enrico Franceschi, Michele Reni
Early metabolic change in 18F-FDG-PET by measuring the single largest lesion predicts chemotherapeutic effects and patients’ survival: PEACH study
Yusuke Tanaka, Yutaka Ueda, Tomomi Egawa-Takata, Shinya Matsuzaki, Eiji Kobayashi, Kiyoshi Yoshino, Takayuki Enomoto, Mitsuaki Tatsumi, Tadashi Kimura
Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer
Faruk Tas, Senem Karabulut, Murat Serilmez, Mehmet Karabulut, Derya Duranyildiz
Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)
Xavier Garcia del Muro, Enrique de Alava, Vicenç Artigas, Silvia Bague, Alejandro Braña, Ricardo Cubedo, Josefina Cruz, Nuria Mulet-Margalef, Jose A. Narvaez, Oscar Martinez Tirado, Claudia Valverde, Ramona Verges, Joan Viñals, Javier Martin-Broto
A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin–docetaxel with or without trastuzumab in locally advanced breast cancer
Taher AL-Tweigeri, Adher AlSayed, Shafika Alawadi, Mohamed Ibrahim, Wafaa Ashour, Hassan Jaafar, Omalkhair Abulkhair, Huda AL-Abdulkarim, Hassan Khalid, Dahish Ajarim
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
Taofeek Kunle Owonikoko, Arif Hussain, Walter Michael Stadler, David C. Smith, Harriet Kluger, Ana M. Molina, Parul Gulati, Aadhar Shah, Christoph Matthias Ahlers, Pina M. Cardarelli, Lewis J. Cohen
A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site
Dong-Yeop Shin, Yoon Hee Choi, Hyo-Rak Lee, Im Il Na, Young Jin Yuh, Bong-Seog Kim, Ik Joo Chung, Woo-Kyun Bae, Hyun-Jeong Shim, Eun-Kee Song, Sung Hyun Yang, Hye Jin Kang
A novelly synthesized phenanthroline derivative is a promising DNA-damaging anticancer agent inhibiting G1/S checkpoint transition and inducing cell apoptosis in cancer cells
Ni Zhen, Qingyuan Yang, Qiong Wu, Xinyi Zhu, Yue Wang, Fenyong Sun, Wenjie Mei, Yongchun Yu
Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells
Xin Miao, Gilbert Koch, Robert M. Straubinger, William J. Jusko
High CYP2C19 phenotypic variability in gastrointestinal cancer patients
K. E. Burns, W.-Y. Lo, M. P. Findlay, K. Sharples, G. Laking, N. A. Helsby
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis
Mariamena Arbitrio, Maria Teresa Di Martino, Vito Barbieri, Giuseppe Agapito, Pietro Hiram Guzzi, Cirino Botta, Eleonora Iuliano, Francesca Scionti, Emanuela Altomare, Stefania Codispoti, Serafino Conforti, Mario Cannataro, Pierfrancesco Tassone, Pierosandro Tagliaferri
Enhanced brain distribution of carboplatin in a primate model after blood–brain barrier disruption using an implantable ultrasound device
Lauriane Goldwirt, Michael Canney, Catherine Horodyckid, Joel Poupon, Samia Mourah, Alexandre Vignot, Jean-Yves Chapelon, Alexandre Carpentier